10-Q: Cyanotech Nears Break-Even in Q2 Amid Sales Surge

Cyanotech Corporation reported a significant turnaround in its second fiscal quarter, achieving near break-even net income driven by strong sales growth and improved gross margins, despite ongoing liquidity concerns.

Summary

• Cyanotech Corporation reported net sales of $6.976 million for the second quarter of fiscal year 2026, an increase of 19.3% compared to $5.845 million in the prior year.
• Gross profit for the second quarter was $2.393 million, with a gross profit margin of 34.3%, significantly up from $1.479 million and 25.3% in the same period last year.
• The company achieved a net income of $1,000 for the second quarter, a substantial improvement from a net loss of $1.150 million in the prior year's quarter.
• For the six months ended September 30, 2025, net sales increased 9.0% to $12.797 million from $11.743 million in the prior year.
• Six-month gross profit was $4.166 million, with a gross profit margin of 32.6%, up from $2.956 million and 25.2% in the prior year.
• The net loss for the six months ended September 30, 2025, was reduced to $925,000, compared to a net loss of $2.352 million in the same period last year.
• Cash at September 30, 2025, increased to $649,000 from $257,000 at March 31, 2025.
• Working capital decreased to $39,000 at September 30, 2025, from $302,000 at March 31, 2025.
• The company continues to operate under a 'going concern' warning due to historical operating losses, negative cash flows, and non-compliance with debt covenants, although waivers have been obtained from its bank.
• Borrowings on the related party line of credit increased to $4.2 million at September 30, 2025, from $3.0 million at March 31, 2025.

Sentiment

Score: 7

Explanation: The company demonstrated significant operational improvements, achieving net income for the quarter and substantially reducing its six-month net loss, driven by strong sales growth and improved gross margins. This positive momentum is tempered by the persistent 'going concern' warning, continued reliance on related-party debt for liquidity, and recurring debt covenant violations, even with waivers.

Positives

• Net sales for the second quarter increased by 19.3% year-over-year to $6.976 million, driven by higher bulk sales and strong e-commerce performance.
• Gross profit margin significantly improved to 34.3% in Q2 fiscal 2026, up 9 percentage points from 25.3% in the prior year, due to higher production volumes and price increases for Nutrex-brand products.
• The company achieved a net income of $1,000 in Q2 fiscal 2026, a substantial turnaround from a net loss of $1.150 million in the same period last year.
• Operating expenses decreased by $251,000 in Q2 fiscal 2026 compared to the prior year, reflecting continued cost management efforts.
• For the six-month period, net sales increased by 9.0% to $12.797 million, primarily due to a 91.1% increase in bulk astaxanthin sales and a 26.7% increase in bulk spirulina sales.
• The six-month net loss was significantly reduced to $925,000 from $2.352 million in the prior year, indicating improved overall financial performance.
• Cash balance increased to $649,000 at September 30, 2025, from $257,000 at March 31, 2025, reflecting increased cash provided by financing activities.

Negatives

• The company continues to sustain operating losses and negative cash flows from operations for most periods, raising substantial doubt about its ability to continue as a going concern.
• Working capital decreased to $39,000 at September 30, 2025, from $302,000 at March 31, 2025, primarily due to timing of customer payments and production scheduling.
• Packaged sales for the six months ended September 30, 2025, decreased by 2.3% for both astaxanthin and spirulina compared to the prior year.
• Contract extraction and R&D services revenue significantly decreased by 85.2% in Q2 and 78.4% for the six months, adversely affected by tariffs on imported biomass.
• The company was not in compliance with two debt covenant requirements (debt service coverage ratio and current ratio) as of March 31, 2025, and March 31, 2024, requiring waivers from the bank.
• Accumulated deficit increased to $(27,029) thousand at September 30, 2025, from $(26,104) thousand at March 31, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to sustained operating losses and negative cash flows.
• Non-compliance with debt covenants (debt service coverage ratio and current ratio) could lead the bank to declare a default, despite current waivers.
• Reliance on funding sources and capital raising is necessary to provide liquidity and meet financing requirements.
• The company's operating plan and cash flow projections are dependent on many factors, some of which are beyond its control, with no assurance of achievement.
• Exposure to local, national, and world economic conditions, including volatility of crude oil prices, inflation, and currency fluctuations.
• Risk of inability to generate sufficient revenues to meet obligations or repay maturing indebtedness.
• Potential for capital projects to fail to operate as expected or meet anticipated results.
• Significant customer concentration risk, with three customers accounting for 74% of accounts receivable at September 30, 2025, and a large portion of net sales.
• Future operating results may fluctuate due to changes in sales volumes to largest customers, weather patterns, increased competition, and increased material, nutrient, and energy costs.
• Government regulations, both domestic and foreign, could impact operations and financial performance.
• Gross profit margins can be negatively impacted by lower production volumes, pressure on input costs, and increased competition.
• The complex biological production process of microalgae is subject to imbalances or unexpected events (strain variation, temperature, acidity, nutrients) that can lead to production levels below normal capacity.
• Unplanned cash outflows may necessitate the use of other cash resources to meet working capital needs.
• A prolonged downturn in sales could impair the ability to generate sufficient cash for operations and attract additional capital investment.

Future Outlook

The company's strategic direction is to be a world leader in the production and marketing of high-value natural products from microalgae, focusing on stabilizing production volume, rationalizing market channel participation, and leveraging core competencies. It will continue to emphasize Nutrex Hawaiian consumer products while exploring further opportunities for bulk sales of spirulina and astaxanthin, both domestically and internationally. Extraction services to third-party customers are expected to generate additional income. The company aims to focus on higher-margin consumer products and continuous improvements in processes and production methods to stabilize costs and production levels, balancing production with sales demand, minimizing inventory costs, and managing expenses judiciously. However, the outlook acknowledges potential impacts from lower production volumes, pressure on input costs, greater competition, and external factors beyond its control.

Management Comments

• Matthew K. Custer, President and CEO, stated: "Our second quarter reflected continued momentum in both sales growth and profitability. Total sales increased 19.3% year-over-year, driven by higher bulk sales and strong performance in our online channels."
• Matthew K. Custer also noted: "We also saw meaningful improvement in gross margin as our production volumes continued to increase, driving lower per-unit costs and better overall efficiency. Additionally, price increases implemented earlier in the year for our Nutrex-brand products contributed to margin expansion."
• Matthew K. Custer further commented: "While tariffs impacted our contract extraction competitiveness, we remain focused on operational excellence, disciplined cost control, and building a stronger, more resilient business positioned for long-term success."
• Matthew K. Custer concluded: "With continued momentum across our brands, improving profitability trends, and a dedicated team that continues to deliver results despite challenging market conditions, I'm confident that Cyanotech is steadily moving in a positive direction."

Industry Context

The company operates in the natural products and dietary supplements market, specifically focusing on microalgae-derived products like Astaxanthin and Spirulina. It notes increased competition in the marketplace and the impact of volatile energy costs and rapidly changing world markets. The filing also highlights that contract extraction sales were adversely affected by tariffs on imported biomass, reducing competitiveness. Furthermore, the company acknowledges that consumers are feeling the impacts of higher inflation, leading to overall lower demand and more cautious discretionary spending, which affects its sales.

Management Changes

Legal Proceedings

• There were no significant legal matters outstanding as of September 30, 2025.

Related Party Transactions

• The company has an unsecured subordinated loan (Skywords Note) from Skywords Family Foundation, Inc., controlled by the Chairman of the Board and largest stockholder, with a principal balance of $1,000,000 as of September 30, 2025, maturing on April 12, 2027.
• The company has a revolving loan facility (Revolver) with Skywords, allowing borrowings up to $4,600,000, with an outstanding balance of $4,200,000 as of September 30, 2025 (up from $3,000,000 at March 31, 2025), maturing on April 12, 2027.
• The Fourth Amendment to the Skywords Note (May 2, 2025) allows the company to elect to pay interest accrued during the fiscal year ended March 31, 2026, in common stock in lieu of cash.
• The Fifth Amendment to the Skywords Note (August 29, 2025) increased the Revolver limit from $4,000,000 to $4,600,000 and extended its maturity to April 12, 2027.
• Interest on the Skywords Note and Revolver accrues at 1% plus the Wall Street Journal prime rate, with a floor of 5% (7.5% at September 30, 2025).

Stakeholder Impact

• Shareholders: Potential for increased value due to improved financial performance, but also risk of dilution from stock grants for directors and potential future interest payments in common stock to a related party. The 'going concern' warning remains a significant concern.
• Employees: Continued cost savings initiatives include maintaining reduced headcount and compensation, primarily through attrition and furloughs.
• Customers: Increased demand for products, particularly bulk sales, and price increases for certain Nutrex-brand packaged products.
• Suppliers: Inventory and raw-material purchases are managed on a just-in-time basis, aligning with sales demand.
• Creditors (First Foundation Bank): Debt covenant violations were waived, but the bank reserves the right to declare a default if future covenants are not met. The bank holds a senior security interest in the company's assets.
• Creditors (Skywords Family Foundation, Inc.): Provided increased revolving credit and extended maturity dates, demonstrating continued support, but holds a subordinated security interest.

Next Steps

• Continue to monitor cost savings initiatives implemented in fiscal year 2023.
• Balance production volume with current customer demand to manage inventory levels effectively.
• Maintain a reduced headcount and compensation, primarily through attrition and furloughs.
• Eliminate certain discretionary selling, general, and administrative expenses.
• Strengthen its eCommerce footprint, optimize marketing efforts, and improve retail strategy by leveraging the newly hired Head of Sales.
• Place emphasis on Nutrex Hawaiian consumer products.
• Explore further opportunities for bulk sales orders for spirulina and astaxanthin, both domestically and internationally.
• Utilize contract extraction and R&D services to third-party customers to generate additional income.
• Strive for continuous improvements in processes and production methods to stabilize costs and production levels.
• Host a virtual broadcast on November 11, 2025, to respond to questions about operating results.

Key Dates

Recommendation

Cyanotech's Q2 fiscal 2026 results show significant operational improvements, including a return to quarterly net income, strong sales growth, and substantial gross margin expansion. These are positive indicators of management's efforts in cost control and market strategy. However, the company continues to carry a 'going concern' warning, relies heavily on related-party financing, and has a history of debt covenant non-compliance, even with recent waivers. While the operational turnaround is encouraging, the underlying financial fragility and dependence on external, often related-party, capital injections present considerable risks. A 'Hold' recommendation is appropriate for a seasoned investor to observe if these positive operational trends can be sustained and if the company can achieve long-term financial stability and address its fundamental liquidity and debt challenges without further significant dilution or reliance on related parties.

Keywords

Microalgae, Astaxanthin, Spirulina, Dietary Supplements, Nutrex Hawaii, Financial Results, SEC Filing, 10-Q, Going Concern, Debt Covenants, Sales Growth, Gross Margin, E-commerce, Hawaii, Natural Products